Lauren Riker, who serves as Senior Vice President of Finance at Pacira BioSciences, Inc. (NASDAQ:PCRX), reported the sale of 4,000 shares of the company’s common stock on February 2, 2026. The block of shares generated proceeds of approximately $83,240 and reflected a weighted average sale price of $20.81 per share. Individual executions within that block ranged from $20.35 to $21.28.
According to the Form 4 filing submitted to the Securities and Exchange Commission, Riker had previously surrendered 2,751 shares on January 30, 2026, to satisfy tax withholding obligations arising from the vesting of restricted stock units. That transaction was recorded at $20.54 per share for a total value of $56,505.
Following the two reported dispositions, Riker is recorded as directly owning 52,313.242 shares of Pacira BioSciences. At the time of reporting the stock traded at $21.02, a price noted as being near the upper end of the range in which the February 2 sales occurred. An analysis flagged by InvestingPro in the filing commentary indicates the stock is considered significantly undervalued relative to its Fair Value assessment.
Beyond the insider activity, Pacira reported full-year 2025 results showing record total revenue of $726.4 million, up from $701.0 million in 2024. The company attributed the increase primarily to the performance of its pain management product, EXPAREL. In the fourth quarter, EXPAREL net product sales totaled $155.8 million, representing a 7% volume increase compared with the same quarter a year earlier.
Pacira has pursued commercial expansion in select Asia-Pacific markets through an exclusive distribution agreement with LG Chem, under which LG Chem will commercialize EXPAREL in those territories. The company also announced a board appointment, adding Samit Hirawat, M.D., which expands the board to 10 members.
Governance developments continue to unfold as investment firm DOMA Perpetual Capital Management LLC intends to nominate three independent director candidates to Pacira’s board and is calling for the immediate sale of the company, according to the company disclosures cited in the filing.
Pacira also published pilot-study results for its iovera° cryoneurolysis treatment, reporting that over a 12-month follow-up period patients treated with iovera° experienced significantly lower pain scores and improved functional outcomes compared with those who received radiofrequency ablation for chronic low back pain.
Additional metrics referenced in filings and data notes show the company maintains a Piotroski Score of 9, and management has been actively repurchasing shares. Pacira’s next earnings report is scheduled for February 19, and investors can access the company’s Pro Research Report available among InvestingPro’s coverage of US equities.
These insider sales, juxtaposed against record revenue, product growth and heightened governance activity, present a multifaceted picture of Pacira’s current corporate status. The disclosures document specific share counts, prices and timing of transactions while leaving interpretive judgments to market participants.